Validation of a Sagittal Section Technique for Measuring Clitoral Blood Flow. Volume Flow: A New Parameter in Clitoral Artery Doppler.

BACKGROUND: Clitoral artery Doppler has been used as an objective technique to measure changes in genital women response. However, the technique has not been fully validated, and arterial volume flow has never been used as an outcome measure. AIMS: To validate the technique clitoral artery Doppler measured in a sagittal section and explore arterial volume flow as a new parameter in clitoral Doppler. METHODS: We examined 90 healthy volunteers by clitoral artery Doppler using the sagittal section approach described by Battaglia et al in 2008. We calculated intraobserver, interobserver, and intraobserver intersession variability and reliability for all Doppler parameters and described and validated arterial volume flow as a new parameter in clitoral artery Doppler. OUTCOMES: We calculated peak systolic velocity (PSV), time-averaged maximum velocity, time-averaged mean velocity, end-diastolic velocity, pulsatility index, resistance index, and volume flow (v-flow) in all groups. We conducted reliability analyses using the intraclass correlation coefficient for agreement. We explored differences between and within observers and calculated agreement limits using the Bland-Altman test. RESULTS: The intraclass correlation coefficient analysis showed correlation values higher than 0.75 (good reliability) for most of the variables and higher than 0.60 (moderate reliability) for the remaining ones. There were statistically significant differences between PSV and time-averaged maximum velocity in the intraobserver intersession measurements. For the remaining groups and variables, no statistically significant differences were observed. Bland-Altman analyses showed that the limits of agreement were acceptable and the regressions were not significant. The v-flow parameter also showed good reliability and low variability between groups. CLINICAL IMPLICATIONS: We found that PSV was not a good outcome measure because of its high intraobserver and intersession variability. Moreover, it is possible to measure v-flow in the clitoral artery using the sagittal technique described by Battaglia et al, and it seems that this measure is reliable and reproducible. This could be the best parameter to assess clinical changes. STRENGTHS & LIMITATIONS: This study provided full validation of the sagittal section approach and of a new parameter, v-flow, which could beuseful for assessing clitoral blood flow. The main limitation of the study is its retrospective nature for validating v-flow. CONCLUSION: We found that clitoral artery Doppler measured using a sagittal approach is a valid and reliable technique for studying clitoral blood flow in women. The v-flow variable is a promising and reliable parameter for measuring changes in clitoral blood flow. Pérez MF, Agís IF, La Calle Marcos P, et al. Validation of a Sagittal Section Technique for Measuring Clitoral Blood Flow: Volume Flow - A New Parameter in Clitoral Artery Doppler. J Sex Med 2020;17:1109-1117.

Papel de ospemifeno en el tratamiento de la atrofia vulvovaginal en la mujer posmenopáusica / Role of ospemifene in the treatment of vulvar and vaginal atrophy in postmenopausal woman

A pesar de que los síntomas de atrofia vulvovaginal (AVV) tienen un impacto significativo en la vida de una mujer, el grado de insatisfacción con las terapias disponibles es elevado. Si además consideramos que muchas mujeres son reacias a aceptar los tratamientos vaginales o no pueden utilizarlos, se hace patente la necesidad médica no cubierta en el manejo de la AVV. Ospemifeno es el primer tratamiento oral que no contiene hormonas indicado para mujeres posmenopáusicas con AVV no candidatas a estrógenos locales, y el único modulador selectivo de los receptores estrogénicos (SERM) con actividad antagonista en la mama, neutral en el útero y agonista en los huesos y vagina. Ospemifeno restaura el epitelio vaginal mejorando significativamente los síntomas de sequedad vaginal y dispareunia, y la salud sexual. Además de un óptimo tratamiento, los profesionales deberían abordar proactivamente la salud vaginal como parte del cuidado de la mujer posmenopáusica, especialmente a la luz del escaso conocimiento que muestran las mujeres acerca de esta condición (AU)

Despite symptoms of vulvar and vaginal atrophy (VVA) can have a significant impact on a woman’s life, the level of dissatisfaction with available VVA treatments is high. If we also consider that many women are reluctant to accept vaginal treatments or are unable to use it, the unmet medical need in the management of VVA becomes evident. Ospemifene is the first oral treatment that does not contain hormones, for post-menopausal women with VVA who are not candidates for local estrogens, and the only SERM with antagonistic effect in breast, neutral in uterus, and agonistic in bone and vagina. Ospemifene restores the vaginal epithelium and show significant improvements in symptoms of vaginal dryness and dyspareunia and therefore in the woman’s sexual function. Besides an optimal treatment, professionals should proactively address the vaginal health as part of postmenopausal women care, particularly in view of survey results highlighting the poor understanding of this condition that women have (AU)